You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, August 2012
|
| DOI | 10.1007/s00262-012-1317-2 |
| Pubmed ID | |
| Authors |
Nadeem A. Sheikh, Daniel Petrylak, Philip W. Kantoff, Corazon dela Rosa, Frances P. Stewart, Ling-Yu Kuan, James B. Whitmore, James B. Trager, Christian H. Poehlein, Mark W. Frohlich, David L. Urdal |
| Abstract |
Sipuleucel-T, the first FDA-approved autologous cellular immunotherapy for treatment of advanced prostate cancer, is manufactured by activating peripheral blood mononuclear cells, including antigen presenting cells (APCs), with a fusion protein containing prostatic acid phosphatase. Analysis of data from three phase 3 trials was performed to immunologically characterize this therapy during the course of the three doses, and to relate the immunological responses to overall survival (OS). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 145 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | <1% |
| Netherlands | 1 | <1% |
| Czechia | 1 | <1% |
| Denmark | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 140 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 29 | 20% |
| Student > Ph. D. Student | 21 | 14% |
| Other | 16 | 11% |
| Student > Bachelor | 15 | 10% |
| Student > Doctoral Student | 13 | 9% |
| Other | 27 | 19% |
| Unknown | 24 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 28% |
| Agricultural and Biological Sciences | 21 | 14% |
| Biochemistry, Genetics and Molecular Biology | 20 | 14% |
| Immunology and Microbiology | 15 | 10% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
| Other | 15 | 10% |
| Unknown | 30 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 January 2023.
All research outputs
#7,197,255
of 23,477,147 outputs
Outputs from Cancer Immunology, Immunotherapy
#969
of 2,932 outputs
Outputs of similar age
#50,212
of 166,048 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#13
of 30 outputs
Altmetric has tracked 23,477,147 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 2,932 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 166,048 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 56% of its contemporaries.